Showing 1 to 11 of 11 entries
  • «
  • 1
  • »
DON'T BUY

Great balance sheet but company is at the US government’s mercy. Will make money but over a longer period of time. He is not a big fan of this story because there are a lot better opportunities out there right now.

biotechnology / pharmaceutical
PAST TOP PICK
(Top Pick Nov 11/10, Down 42.22%) Revenues are down. Major positive is a new CEO with a good track record came on a while ago. This company could be sold in a take-over, perhaps.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Nov 11/10. Down 51.45%.) Sold his personal holdings at $3.18. Recently have had some good news. The new CEO has a good track record and a lot of potential. Lots of cash and a good balance sheet but they don't have enough products to sell.
biotechnology / pharmaceutical
PAST TOP PICK
(Top Pick Nov 11/10, Down 56.50%) He got out of it personally but fund has it. Heard quarterly numbers were going to be bad and didn’t see it turning around for quite a while. New CEO that came on in August has quite a track record.
biotechnology / pharmaceutical
WAIT
On the buy list (his partner’s). The CEO was booted out a little while ago. Company had problems because of major product in the states. It is going to spread out revenues over time. Moves sales force in-house. Need economies of scale to boost the bottom line. He says he would wait for it to go a little higher.
biotechnology / pharmaceutical
HOLD
Undergoing tremendous changes. Looking for new products. They are looking to make an acquisition to expand product line.
biotechnology / pharmaceutical
BUY
A Contrarian pick in the pharma sector. Did well post-911 when people were bulking up on certain drugs. Management was a little optimistic about how well they could replace those drugs in the pipeline. He would expect it to suddenly jump out of the box.
biotechnology / pharmaceutical
DON'T BUY
Would recommend that you stay away from this one because there is no predictability from year to year on their earnings.
biotechnology / pharmaceutical
TOP PICK
Some risks as revenues have gone down year to year from $240 million to $160 million. Marginal in terms of profitability from $60 million to $8 million. Has been profitable for most of the past 8 years. Good management and no debt and over $40 million in cash.
biotechnology / pharmaceutical
HOLD
Past pick. 13% increase... doing well. Be content to hold.
biotechnology / pharmaceutical
TOP PICK
Good earnings/revenues.
biotechnology / pharmaceutical
Showing 1 to 11 of 11 entries
  • «
  • 1
  • »

Cangene Corp(CNJ-T) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Cangene Corp is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Cangene Corp(CNJ-T) Frequently Asked Questions

What is Cangene Corp stock symbol?

Cangene Corp is a OTC stock, trading under the symbol CNJ-T on the (). It is usually referred to as or CNJ-T

Is Cangene Corp a buy or a sell?

In the last year, there was no coverage of Cangene Corp published on Stockchase.

Is Cangene Corp a good investment or a top pick?

Cangene Corp was recommended as a Top Pick by on . Read the latest stock experts ratings for Cangene Corp.

Why is Cangene Corp stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Cangene Corp worth watching?

In the last year, there was no coverage of Cangene Corp published on Stockchase.

What is Cangene Corp stock price?

On , Cangene Corp (CNJ-T) stock closed at a price of $.